Efficacy of Inclisiran for Dyslipidemia

Efficacy of Inclisiran for Dyslipidemia - Efficacy of Inclisiran for Dyslipidemia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053986

Enrollment

Registered

2024-03-27

Start date

2024-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

yslipidemia(Receiving evolocumab or taking maximum tolerated dose of statins)

Interventions

Inclisiran administered to patients with treatment-resistant dyslipidemia (initial, 3 months, 9 months, and 15 months after initial administration)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving evolocumab or maximum tolerated dose of statins

Exclusion criteria

Exclusion criteria: Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
LDL	—

Secondary

Measure	Time frame
1) HDL, T-cho, TG, RLP-cho, Lp(a) 2) BUN, Cr, eGFR, cystatin C 3) AST, ALT 4) Fatty acid 5) FMD, ABI 6) cardiovascular event, death 7) side effect	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3982-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026